Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 5, 2007, Pages 763-771

  Rolleman, Edgar J ^a   Forrer, Flavio ^a   Bernard, Bert ^a   Bijster, Magda ^a   Vermeij, Marcel ^a   Valkema, Roelf ^a   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amifostine; Kidney; Lutetium; Octreotate; PRRT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMIFOSTINE; LUTETIUM 177; LYSINE; OCTREOTATE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177]; PEPTIDE; RADIOISOTOPE; SUCCIMER TC 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOLLOW UP; HISTOLOGY; KIDNEY INJURY; KIDNEY TUBULE; KIDNEY TUBULE FUNCTION; MALE; NONHUMAN; PROTEINURIA; RADIOISOTOPE THERAPY; RAT; RENAL PROTECTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WEIGHT REDUCTION;

AMIFOSTINE; ANIMALS; BODY WEIGHT; CREATININE; KIDNEY; LYSINE; MALE; NEOPLASMS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PROTEINURIA; RADIATION INJURIES; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34247590300     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0291-3     Document Type: Article

References (35)

1. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S-6S.
2. 90Y-DOTATOC. J Nucl Med 2002;43:610-6.
3. 3]octreotate in patients with endocrine gastroentero-pancreatic tumors. J Clin Oncol 2005;23:2754-62.
4. 3]octreotate. J Clin Oncol 2004;22:2724-9.
5. 3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147-56.
6. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 1993;34:1728-38.
7. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S-106S.
8. De Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging, 2003;30:463-9.
9. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
10. De Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388-92.
11. Rolleman EJ, Valkema R, De Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15.
12. Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 2004;19:2275-81.
13. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-16.
14. 3] octreotate in rats. Eur J Nucl Med Mol Imaging 2006 Sep 22; [Epub ahead of print].
15. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol 2003;23:486-99.
16. Andreassen CN, Grau C, Lindegaard JC. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 2003;13:62-72.
17. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med 1985;47:23-7.
18. Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996;23:2-17.
19. 0]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
20. 177Lu. J Nucl Med 2004;45:1260-9.
21. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-33.
22. Forrer F, Valkema R, Bernard B, Hoppin J, Schramm N, Rolleman EJ, et al. In vivo radionuclide uptake quantification using a multipinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging, 2006; in press.
23. Asna N, Lewy H, Ashkenazi IE, Deutsch V, Peretz H, Inbar M, et al. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity. Life Sci 2005;76:1825-34.
24. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993;72:3495-501.
25. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 2003;57:794-802.
26. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999;26:3-21.
27. Culy CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001;61:641-84.
28. Vardy J, Wong E, Izard M, Clifford A, Clarke SJ. Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anticancer Drugs 2002;13:327-30.
29. Lin A, Lawrence TS. An anaphylactoid reaction from amifostine. Radiother Oncol 2006;79:352.
30. Demiral AN, Yerebakan O, Simsir V, Alpsoy E. Amifostineinduced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol 2002;32:477-9.
31. Boccia R. Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Semin Oncol 2002;29:9-13.
32. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18:2226-33.
33. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 2002;29:80-3.
34. Block KI, Gyllenhaal C. Commentary: the pharmacological antioxidant amifostine - implications of recent research for integrative cancer care. Integr Cancer Ther 2005;4:329-51.
35. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radio-therapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006;64:784-91.